‘Hallucinogenic Drugs and Central Transmitter Substances’

References

• Abood L. G. The psychotomimetic glycollate esters. Drugs affecting the Central Nervous System, A. Burger. Pub. Edward Arnold, London 1968; 2: 127–167
   Google Scholar
• Abood L. G., Biel J. H. Anticholinergic psychotomimetic agents. Int. Rev. Neurbiol. 1962; 4: 218–273
   Google Scholar
• Aghajanian G. K., Foote W. E., Sheard M. H. Lysergic acid diethylamide: sensitive neuronal units in the mid-brain rophe. Science 1968; 161: 706–708
   PubMed Web of Science ®Google Scholar
• Aghajanian G. K., Foote W. E., Sheard M. H. Action of psychotogenic drugs on single mid-brain raphe neurons. J. Pharmac. exp. therap. 1970; 171: 178–187
   PubMedGoogle Scholar
• Andén N.-E. On the mechanism of noradrenaline depletion by alphamethyl metratyrosine and metera-minol. Acta Pharmacol, et Toxicol. 1964; 21: 260–271
   PubMedGoogle Scholar
• Andén N.-E., Corrodi H., Fuxe K., Hokfelt T. Evidence for a central 5-hydroxytryptamine receptor stimulation by lysergic diethylamide. Br. J. Pharmac. 1968; 34: 1–7
   PubMed Web of Science ®Google Scholar
• Antun F., Smythies J. R. Binding of tryptamine and allied compounds to nucleic acids. Nature 1969; 223: 1061–1063
   PubMed Web of Science ®Google Scholar
• Baird J. R. C., Lewis J. J. The effects of cocaine, amphetamine and some amphetamine-like compounds on the in vivo levels of noradrenaline and dopamine in the rat brain. Biochem. Pharmac. 1964; 13: 1475–1482
   PubMedGoogle Scholar
• Balestrieri A., Fontanari D. Acquired and cross tolerance to mescaline. Arch. gen. Psychiat. 1959; 9: 279–282
   Google Scholar
• Carlsson A., Fuxe K., Hamberger B., Malmfors J. Effect of a new series of bicyclic compounds with potential thymoleptic properties on the reserpine resistant uptake mechanism of central and peripheral neurones in vitro and in vivo. Br. J. Pharmac. 1969; 36: 18–28
   PubMedGoogle Scholar
• Carlsson A., Lindquist M., Dahlstrom A., Fuxe K., Masuoka D. Effects of the amphetamine group on intraneuronal brain amines in vivo and in vitro. J. Pharmac 1965; 17: 521–523
   Google Scholar
• Carlsson A., Corrodi H., Fuxe K., Hokefelt T. Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4 methyl-a-ethyl-meta-tyramine. Eur. J. Pharmac. 1969; 5: 357–366
   PubMed Web of Science ®Google Scholar
• Cerletti A., Doepfner W. Comparative study on the serotonin antagonism of amide derivatives of lysergic acid and of ergot alkaloids. J. Pharmac. Exp. therap. 1958; 122: 124–136
   PubMedGoogle Scholar
• Conell P. H. Amphetamine Psychosis. Maudesley Monographs, No. 5, London 1958
   Google Scholar
• Come S. J., Pickering R. W., Warner B. J. A method for assessing the effects of drugs on the central actions of 5-hydroxytryptamine. Br. J. Pharmac. 1963; 20: 106–120
   Google Scholar
• Curtis D. R., Watkins J. C. The pharmacology of amino acids related to a-aminobutyric acid. Pharmac. Rev. 1965; 17: 347–391
   PubMed Web of Science ®Google Scholar
• Denber H. C. B., Teller D. N. Studies on mescaline XIX: A new theory concerning the nature of schizophrenia. Psychosomatics 1968; 9: 145–151
   PubMedGoogle Scholar
• Faillace L. A., Snyder S. H., Weincartner H. 2,5-Dimethoxy-4-methylamphetamine: clinical evaluation of a new hallucinogenic drug. J. Nerv. ment. dis. 1970; 150: 119–126
   PubMedGoogle Scholar
• Freedman D. X. Effects of LSD25 on brain seratonin. J. Pharmac. exp. therap. 1961; 134: 160–166
   PubMedGoogle Scholar
• Freedman D. X. Psychotomimetic drugs and brain biogenic amines. Am. J. Psychiat. 1963; 119: 843
   PubMedGoogle Scholar
• Freedman D. X., Aghajanian G. K. Time parameters in acute tolerance, cross tolerance and antagonism to psychotogens. Fed. Proc 1959; 18: 390
   Google Scholar
• Freedman D. X., Giarman N. J. LSD25 and the status and level of brain serotonin. Am. N. Y. Acad. Sci. 1962; 96–106
   PubMedGoogle Scholar
• Gaddum J. H. Antagonism between lysergic acid diethylamide and 5-hydroxtryptamine. J. Physiol. 1953; 121: 15P
   PubMed Web of Science ®Google Scholar
• Garattini S. Effect of cannabis extract on gross behaviour. Hashish, Its Chemistry andPharmarcology, G. E. W. Wolstenshome, J. Knight. Pub. Churchill. 1965; 70
   Google Scholar
• Giarman N. J., Freedman D. X. Biochemical aspects of the action of psychotomimetic drugs. Pharmac. Rev. 1965; 17: 1–25
   PubMedGoogle Scholar
• Green J. P. Histamine and the nervous system. Fed. Proc 1964; 23: 1095–1102
   PubMedGoogle Scholar
• Greifenstein F. E., Devault M., Yoshitake J., Gajewski J. E. A study of a I-aryl cyclohexylamine for anaesthesia. Anaesth. and Analges. 1958; 37: 283–294
   PubMedGoogle Scholar
• Heath R. G. Recent Advances in Biological Psychiatry, J. Wortis. Pub. Grime and Strathon, N.Y. 1961; 164
   Google Scholar
• Hofman A. Psychotomimetic drugs–chemical and pharmacological aspects. Acta physiol. pharm. need. 1959; 8: 240–258
   PubMedGoogle Scholar
• Iversen L. L., Axelrod J., Glowinski J. The effect of antidepressant drugs on the uptake and metabolism of catecholamines in the brain. Proc. 5th Int. Cong.; Coll. Int. Neuropsychopharmac, Brill, et al. Pub., Washington 1967; 362–366
   Google Scholar
• Isbell H., Gorodetzsky C. W., Jasinski D., Claussen U., Spulak F., Korte F. Effects of (–) A 9-trans- tetrahydrocannabinol in man. Psychopharmacologia 1967; 11: 184–188
   PubMed Web of Science ®Google Scholar
• Knoll J. Psychotomimetic effects of amphetamines. Amphetamine and Related Compounds, Proc Mario Negri Institute for Pharmacol. Res. Milan 1970; 761
   Google Scholar
• Knoll J., Vizi E. S., Ecseri Z. Psychotomimetic methylamphetamine derivatives. Arch. Int. Phar-macodyn. 1966; 159: 442–451
   PubMedGoogle Scholar
• Koe B. K., Weisman A. p-Chlorophenylalamine: a specific depleter of brain serotonin. J. Pharmac. exp. therap. 1966; 154: 499
   PubMed Web of Science ®Google Scholar
• Keup W. Structure-activity relationships among hallucinogenic agents. Origin, and mechanisms of Hallucinations, W. Keup. Pub. Plenum Press, N.Y. 1970; 345–376
   Google Scholar
• Krnjevic K., Schwartz S. Cortical inhibition and GABA. Fed. Proc. 1966; 25: 627
   Google Scholar
• Krnjevic K., Randic M., Straughan D. W. Pharmacology of cortical inhibition. J. Physiol. 1966; 184: 78–105
   PubMedGoogle Scholar
• Leonard B. E. Cannabis: a short review of its effects and possible dangers of its use. Br. J. Addict. 1968; 64: 121–130
   Google Scholar
• Leonard B. E. The effect of four amphetamines on brain biogenic amines and their metabolites. Biochem. Pharmac 1972; 21: 1289–1297
   PubMed Web of Science ®Google Scholar
• Leonard B. E. The effect of A 1.6 tetrahydro-cannabinal on biogenic amines and their amino acid precursors in the rat brain. Pharmac. Res. Comm. 1971; 3: 139–145
   Google Scholar
• Leonard B. E., Tonge S. R. The effects of some hallucinogenic drugs upon the metabolism of noradrenaline. Life Sci. 1969a; 8: 815–825, pt. 1
   PubMed Web of Science ®Google Scholar
• Leonard B. E., Tonge S. R. Some effects of a hallucinogenic drug (phencyclidine) on neurohumosal substances. Life. Sci. 1970; 9: 1141–1152, pt. 1
   Google Scholar
• Leonard B. E., Shallice S. A. Some neurochemical effects of amphetamines methylamphetamine and p-bromomethylampheramine in the rat. Br. J. Pharmac 1971a; 41: 198–212
   PubMed Web of Science ®Google Scholar
• Leonard B. E., Shallice S. A. Effect of p-nitro-methylamphetamine on biogenic amines and their amino acid precursors in rat brain. Br. J. Pharmac. 1971b, (in Press)
   Google Scholar
• Littleton J. M. The interaction of dexamphetamine with inhibitors of noradrenalin biosynthesis in rat brain in vivo. J. Pharm. Pharmac. 1967; 19: 414–415
   PubMedGoogle Scholar
• Meyer J. S., Greifenstein F., De Vault M. A new drug causing symptoms of sensory deprivation; neurological electroencephalographie and pharmacological effects if Sernyl. J. Nerv. ment. dis. 1959; 129: 54–61
   Web of Science ®Google Scholar
• McLean J. R., McArtney M. Effect of D-amphetamine on rat brain noradrenaline and serotonin. Proc. soc. exp. Biol. Med. 1961; 107: 77–79
   PubMedGoogle Scholar
• Moore K. E., Lariviere E. W. Effects of D-amphetamine and restraint on the content of norepinephrine and dopamine in rat brain. Biochem. Pharmac. 1963; 12: 1283–1288
   PubMedGoogle Scholar
• Schildkraut J. J., Efron D. H. The effect of A 9-tetrahydrocannabinal on the metabolism of norepinephrine in rat brain. Psychopharmacologia 1971; 20: 191–196
   PubMed Web of Science ®Google Scholar
• Smythies J. R., Benington F., Morin R. D. Specification of a possible seratonin receptor site in the brain. N.R.P. Bulletin 1970; 8: 117–122
   Google Scholar
• Smythies J. R., Beaton J., Benington F., Morin R. P. Behavioural effects of some derivaties of amphetamines and LSD and their significance. Nature 1970; 226: 644–645
   PubMedGoogle Scholar
• Smythies J. R., Johnston V. S., Bradley R. J. Behavioural models of psychosis. Br. J. Psychiat. 1969; 115: 55–68
   PubMedGoogle Scholar
• Snyder S. H., Faillace L., Hollister L. 2,5-Dime-thoxy-4-methyl amphetamine (STP): a new hallucinogenic drug. Science 1967; 158: 669–671
   PubMed Web of Science ®Google Scholar
• Snyder S. N., Merril C. R. A relationship between the hallucinogenic activity of drugs and their electronic configuration. Proc. Nat. Acad. Sci. 1965; 54: 258–266
   PubMed Web of Science ®Google Scholar
• Marijuana, and Health. Am. J. Psychiat. 1971; 129: 189, Special report on
   Google Scholar
• Tolentino I. Psychotic recreations and psychosis due to β-phenylisopropylamine and sympathomimetic drugs (amphetamine group). Psychotropic Drugs, Garattini, Ghetti. Pub. Elsemis, Amsterdam 1957; 585
   Google Scholar
• Tonge S. R., Leonard B. E. The effects of some hallucinogenic drugs on the metabolism of 5-hydroxy-tryptamine in the brain. Life Sci. 1969; 8: 805–814, pt. 1
   PubMedGoogle Scholar
• Tonge S. R., Leonard B. E. The effects of some hallucinogenic drugs on the amino acid precursors of brain monoamines. Life Sci. 1970; 9: 1327–1335, pt. 1
   Google Scholar
• Tonge S. R., Leonard B. E. Some observations on the behavioural effects of hallucinogenic drugs on rat: potentiation by two drugs affecting monoamine metabolism. Arch. int. Pharmacodyn 1972a; 195: 168–176
   PubMedGoogle Scholar
• Tonge S. R., Leonard B. E. Hallucinogens and non-hallucinogens: a comparison of the effects on 5-hydroxytryptamine and noradrenaline. Life Sci. 1971b; 10: 161–168, pt. 1
   Google Scholar
• Vane J. R. The actions of sympathomimetic amines on tryptamine receptors. Adrenergic Mechanisms, Vane, Wolstenholme, O'Connor. Pub. Churchill, London 1960; 356–372
   Google Scholar
• Wolley D. W., Shaw E. A biological and pharmacological suggestion about certain mental disorders. Proc. Nat. Acad. Sci. 1954; 40: 228–231
   PubMedGoogle Scholar
• Wooton B. H.M.S.O. 1968, Report of the select committee on Cannabis, (Dec. 1968)
   Google Scholar
• Youdin M. B. H., Sandler M. Activation of mono amine oxidase by reserpine. Eur. J. Pharmac. 1968; 4: 105–108
   PubMedGoogle Scholar